$THC
TENET HEALTHCARE CORP Stock $thc

$thc Overview Financials Valuation SEC Filings Company Website

2014 Q1 Form 10-K Financial Statement

#000110465914012768 Filed on February 24, 2014

Income Statement

Concept	2014 Q1	2013 Q4	2013
Revenue	$3.926B	$3.885B	$11.10B
YoY Change	64.47%	66.67%	21.75%
Cost Of Revenue	$628.0M	$626.0M	$1.784B
YoY Change	63.54%	61.34%	14.95%
Gross Profit	$3.298B	$3.259B	$9.318B
YoY Change	64.65%	67.73%	23.14%
Gross Profit Margin	84.0%	83.89%	83.93%
Selling, General & Admin	$1.921B	$1.872B	$5.371B
YoY Change	59.68%	71.59%	26.17%
% of Gross Profit	58.25%	57.44%	57.64%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$193.0M	$191.0M	$545.0M
YoY Change	69.3%	64.66%	26.74%
% of Gross Profit	5.85%	5.86%	5.85%
Operating Expenses	$3.104B	$3.006B	$8.521B
YoY Change	68.42%	74.46%	25.42%
Operating Profit	$170.0M	$253.0M	$663.0M
YoY Change	16.44%	15.0%	-11.48%
Interest Expense	$182.0M	-$182.0M	$474.0M
YoY Change	76.7%	65.45%	15.05%
% of Operating Profit	107.06%	-71.94%	71.49%
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.00M	-$15.00M	-$158.0M
YoY Change	-91.04%	-115.46%	-147.31%
Income Tax	-$1.000M	-$8.000M	-$65.00M
% Of Pretax Income
Net Earnings	-$16.00M	-$24.00M	-$104.0M
YoY Change	-80.72%	-148.98%	-178.2%
Net Earnings / Revenue	-0.41%	-0.62%	-0.94%
Basic Earnings Per Share	-$0.33		-$1.32
Diluted Earnings Per Share	-$0.33	-$243.4K	-$1.32
COMMON SHARES
Basic Shares Outstanding	96.99M shares	99.23M shares	101.6M shares
Diluted Shares Outstanding			101.6M shares

Balance Sheet

Concept	2014 Q1	2013 Q4	2013
SHORT-TERM ASSETS
Cash & Short-Term Investments	$141.0M	$113.0M	$113.0M
YoY Change	48.42%	-68.96%	-68.96%
Cash & Equivalents	$141.0M	$113.0M	$113.0M
Short-Term Investments
Other Short-Term Assets	$839.0M	$789.0M	$1.429B
YoY Change	84.4%	72.27%	75.99%
Inventory	$261.0M	$262.0M	$260.0M
Prepaid Expenses
Receivables	$2.141B	$1.965B	$1.890B
Other Receivables	$19.00M	$0.00	$0.00
Total Short-Term Assets	$3.978B	$3.710B	$3.692B
YoY Change	62.83%	38.38%	37.71%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.723B	$7.691B	$7.582B
YoY Change	79.77%	79.15%	73.07%
Goodwill	$3.070B	$3.042B
YoY Change	223.84%	232.1%
Intangibles
YoY Change
Long-Term Investments	$355.0M	$56.00M	$357.0M
YoY Change	117.79%	154.55%	573.58%
Other Assets	$333.0M	$347.0M	$347.0M
YoY Change	-30.48%	1.46%	-21.85%
Total Long-Term Assets	$12.51B	$12.42B	$12.76B
YoY Change	93.23%	95.19%	100.5%
TOTAL ASSETS
Total Short-Term Assets	$3.978B	$3.710B	$3.692B
Total Long-Term Assets	$12.51B	$12.42B	$12.76B
Total Assets	$16.48B	$16.13B	$16.45B
YoY Change	84.9%	78.35%	81.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.019B	$1.075B	$1.085B
YoY Change	63.04%	48.89%	50.28%
Accrued Expenses	$869.0M	$820.0M	$820.0M
YoY Change	84.11%	51.85%	51.85%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$622.0M	$153.0M	$153.0M
YoY Change	1096.15%	62.77%	62.77%
Total Short-Term Liabilities	$3.336B	$2.928B	$3.093B
YoY Change	115.36%	66.08%	75.44%
LONG-TERM LIABILITIES
Long-Term Debt	$10.61B	$10.70B	$10.70B
YoY Change	97.43%	107.37%	107.37%
Other Long-Term Liabilities	$453.0M	$446.0M	$1.443B
YoY Change	-25.86%	46.23%	62.32%
Total Long-Term Liabilities	$453.0M	$446.0M	$12.14B
YoY Change	-25.86%	46.23%	100.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.336B	$2.928B	$3.093B
Total Long-Term Liabilities	$453.0M	$446.0M	$12.14B
Total Liabilities	$15.36B	$15.01B	$15.70B
YoY Change	96.13%	92.13%	98.65%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.454B	-$1.422B
YoY Change	5.67%	10.4%
Common Stock	$7.000M	$7.000M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$2.378B	$2.378B
YoY Change	14.44%	20.16%
Treasury Stock Shares	47.20M shares	47.20M shares
Shareholders Equity	$728.0M	$755.0M	$755.0M
YoY Change
Total Liabilities & Shareholders Equity	$16.48B	$16.13B	$16.45B
YoY Change	84.9%	78.35%	81.89%

Cashflow Statement

Concept	2014 Q1	2013 Q4	2013
OPERATING ACTIVITIES
Net Income	-$16.00M	-$24.00M	-$104.0M
YoY Change	-80.72%	-148.98%	-178.2%
Depreciation, Depletion And Amortization	$193.0M	$191.0M	$545.0M
YoY Change	69.3%	64.66%	26.74%
Cash From Operating Activities	-$19.00M	$255.0M	$589.0M
YoY Change	-40.63%	-0.39%	-0.67%
INVESTING ACTIVITIES
Capital Expenditures	$281.0M	-$293.0M	$691.0M
YoY Change	111.28%	97.97%	36.56%
Acquisitions	$9.000M		$1.515B
YoY Change	80.0%		618.01%
Other Investing Activities	$0.00	-$1.362B	-$3.000M
YoY Change	-100.0%	710.71%	-25.0%
Cash From Investing Activities	-$291.0M	-$1.655B	-$2.164B
YoY Change	179.81%	423.73%	226.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$338.0M	1.431B	$1.324B
YoY Change	-354.14%	319.65%	313.75%
NET CHANGE
Cash From Operating Activities	-$19.00M	255.0M	$589.0M
Cash From Investing Activities	-$291.0M	-1.655B	-$2.164B
Cash From Financing Activities	$338.0M	1.431B	$1.324B
Net Change In Cash	$28.00M	31.00M	-$251.0M
YoY Change	-110.41%	-88.97%	-200.0%
FREE CASH FLOW
Cash From Operating Activities	-$19.00M	$255.0M	$589.0M
Capital Expenditures	$281.0M	-$293.0M	$691.0M
Free Cash Flow	-$300.0M	$548.0M	-$102.0M
YoY Change	81.82%	35.64%	-217.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	407000000	USD
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	28000000	USD
CY2013Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	10839000000	USD
CY2012Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	119000000	USD
CY2012Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	116000000	USD
CY2012Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	5252000000	USD
CY2013Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle Within One Year FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleWithinOneYear	149000000	USD
CY2013Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle In Year Two FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleInYearTwo	539000000	USD
CY2013Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayment Of Principle In Year Three FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentOfPrincipleInYearThree	430000000	USD
CY2013Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle In Year Four FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleInYearFour	49000000	USD
CY2013Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principle In Year Five FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipleInYearFive	1047000000	USD
CY2013Q4	us-gaap	Five Year Schedule Of Maturities Of Parent Company Repayments Of Principal After Year Five FiveYearScheduleOfMaturitiesOfParentCompanyRepaymentsOfPrincipalAfterYearFive	8653000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	663000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	137000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	117000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	102000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	80000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	56000000	USD
CY2013Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	171000000	USD
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10867000000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	156000000	USD
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	143000000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	186000000	USD
CY2013	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	8000000	USD
CY2012	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	8000000	USD
CY2012	us-gaap	Dividends Preferred Stock DividendsPreferredStock	11000000	USD
CY2011	us-gaap	Operating Leases Rent Expense Sublease Rentals1 OperatingLeasesRentExpenseSubleaseRentals1	8000000	USD
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	2776320	shares
CY2013	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P3Y3M18D
CY2013Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	30.79
CY2013Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	30.66
CY2013Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	3308111	shares
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7787000000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11589000000	USD
CY2013	thc	Number Of Hospitals Operated By Subsidiaries NumberOfHospitalsOperatedBySubsidiaries	77	item
CY2013	thc	Number Of Licensed Beds In Hospitals Operated By Subsidiaries NumberOfLicensedBedsInHospitalsOperatedBySubsidiaries	20293	item
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1076000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1715000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	224000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	206000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	126000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	82000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	77000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	387000000	USD
CY2012Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15000000	USD
CY2013Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	62000000	USD
CY2013Q4	us-gaap	Equity Method Investments EquityMethodInvestments	56000000	USD
CY2013Q4	us-gaap	Long Term Investments LongTermInvestments	118000000	USD
CY2013Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	25000000	USD
CY2013Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	35000000	USD
CY2013Q4	thc	Land Held For Expansion Long Term Receivables And Other Assets Noncurrent LandHeldForExpansionLongTermReceivablesAndOtherAssetsNoncurrent	227000000	USD
CY2013	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	15000000	USD
CY2012Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22000000	USD
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	37000000	USD
CY2012Q4	us-gaap	Cash Surrender Value Of Life Insurance CashSurrenderValueOfLifeInsurance	21000000	USD
CY2012Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	16000000	USD
CY2012Q4	thc	Land Held For Expansion Long Term Receivables And Other Assets Noncurrent LandHeldForExpansionLongTermReceivablesAndOtherAssetsNoncurrent	88000000	USD
CY2012	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	8000000	USD
CY2013Q4	thc	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	1000000	USD
CY2012Q4	thc	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	1000000	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2310000	shares
CY2013Q4	us-gaap	Escrow Deposit EscrowDeposit	0	USD
CY2012	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	92000000	USD
CY2011	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	108000000	USD
CY2013	us-gaap	Malpractice Loss Contingency Claims Incurred Net MalpracticeLossContingencyClaimsIncurredNet	112000000	USD
CY2011	thc	Number Of Lawsuits NumberOfLawsuits	2	item
CY2011	thc	Number Of Medical Office Buildings Sold NumberOfMedicalOfficeBuildingsSold	7	item
CY2013Q4	us-gaap	Interest Payable Current InterestPayableCurrent	198000000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	125000000	USD
CY2013Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	719000000	USD
CY2012Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	343000000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2928000000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1763000000	USD
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	10690000000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	5158000000	USD
CY2013Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	543000000	USD
CY2012Q4	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	292000000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	446000000	USD
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	405000000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	305000000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	15005000000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	7810000000	USD
CY2013Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	247000000	USD
CY2012Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	16000000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	7000000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4572000000	USD
CY2012Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4471000000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-24000000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-68000000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1422000000	USD
CY2013Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	878000000	USD
CY2012Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1218000000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1288000000	USD
CY2013Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2378000000	USD
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1979000000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	755000000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1143000000	USD
CY2013Q4	us-gaap	Minority Interest MinorityInterest	123000000	USD
CY2012Q4	us-gaap	Minority Interest MinorityInterest	75000000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16130000000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9044000000	USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	401000000	USD
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3494000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	426000000	USD
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	142363915	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	37730431	shares
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	589000000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3898000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	523000000	USD
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	262500000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	144057351	shares
CY2013Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	47197722	shares
CY2013	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	12074000000	USD
CY2012	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	9904000000	USD
CY2011	thc	Health Care Organization Revenue Gross HealthCareOrganizationRevenueGross	9371000000	USD
CY2013	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	972000000	USD
CY2012	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	785000000	USD
CY2011	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	717000000	USD
CY2013	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	11102000000	USD
CY2012	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	9119000000	USD
CY2011	us-gaap	Health Care Organization Revenue HealthCareOrganizationRevenue	8654000000	USD
CY2013	us-gaap	Labor And Related Expense LaborAndRelatedExpense	5371000000	USD
CY2012	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4257000000	USD
CY2011	us-gaap	Labor And Related Expense LaborAndRelatedExpense	4015000000	USD
CY2013	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1784000000	USD
CY2012	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1552000000	USD
CY2011	us-gaap	Health Care Organization Medical Supplies And Drugs Expense HealthCareOrganizationMedicalSuppliesAndDrugsExpense	1548000000	USD
CY2013	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2701000000	USD
CY2012	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2147000000	USD
CY2011	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	2020000000	USD
CY2013	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-96000000	USD
CY2011	us-gaap	Interest Expense InterestExpense	375000000	USD
CY2013	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-348000000	USD
CY2012	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4000000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	663000000	USD
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	749000000	USD
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	653000000	USD
CY2013	us-gaap	Interest Expense InterestExpense	474000000	USD
CY2012	us-gaap	Interest Expense InterestExpense	412000000	USD
CY2011	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-117000000	USD
CY2013	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
CY2012	us-gaap	Gain Loss On Investments GainLossOnInvestments	1000000	USD
CY2011	us-gaap	Gain Loss On Investments GainLossOnInvestments	3000000	USD
CY2013Q4	us-gaap	Assets Held For Sale Long Lived AssetsHeldForSaleLongLived	44000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-158000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	334000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	164000000	USD
CY2012	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	211000000	USD
CY2013	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-65000000	USD
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	125000000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113000000	USD
CY2012	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-40000000	USD
CY2011	thc	Electronic Health Record Incentives ElectronicHealthRecordIncentives	-55000000	USD
CY2013	us-gaap	Depreciation And Amortization DepreciationAndAmortization	545000000	USD
CY2012	us-gaap	Depreciation And Amortization DepreciationAndAmortization	430000000	USD
CY2011	us-gaap	Depreciation And Amortization DepreciationAndAmortization	398000000	USD
CY2013	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1515000000	USD
CY2013	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-31000000	USD
CY2012	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-5000000	USD
CY2011	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	-55000000	USD
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	61000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-93000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	209000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	103000000	USD
CY2013	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-5000000	USD
CY2012	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-2000000	USD
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax	-18000000	USD
CY2013	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	0	USD
CY2012	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	100000000	USD
CY2011	thc	Discontinued Operation Restructuring Settlement And Impairment Provisions Before Income Tax DiscontinuedOperationRestructuringSettlementAndImpairmentProvisionsBeforeIncomeTax	6000000	USD
CY2013	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	2000000	USD
CY2012	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	0	USD
CY2011	thc	Litigation And Investigation Costs LitigationAndInvestigationCosts	17000000	USD
CY2013	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2012	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	1000000	USD
CY2011	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	0	USD
CY2013	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	4000000	USD
CY2012	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-25000000	USD
CY2011	us-gaap	Discontinued Operation Tax Effect Of Discontinued Operation DiscontinuedOperationTaxEffectOfDiscontinuedOperation	-32000000	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-11000000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-76000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-9000000	USD
CY2013	us-gaap	Profit Loss ProfitLoss	-104000000	USD
CY2012	us-gaap	Profit Loss ProfitLoss	133000000	USD
CY2011	us-gaap	Profit Loss ProfitLoss	94000000	USD
CY2013	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2164000000	USD
CY2011	us-gaap	Dividends Preferred Stock DividendsPreferredStock	24000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	30000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	13000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations Attributable To Noncontrolling Entity IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity	11000000	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	0	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	-32000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Noncontrolling Interest IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest	1000000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-134000000	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	58000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-123000000	USD
CY2011	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	44000000	USD
CY2013	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-15000000	USD
CY2012	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-35000000	USD
CY2011	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-38000000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	589000000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	593000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	497000000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	691000000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	506000000	USD
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	467000000	USD
CY2013	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	0	USD
CY2012	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	2000000	USD
CY2011	thc	Payments To Acquire Property Plant And Equipment For Discontinued Operations PaymentsToAcquirePropertyPlantAndEquipmentForDiscontinuedOperations	8000000	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	12000000	USD
CY2013	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	16000000	USD
CY2012	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	45000000	USD
CY2011	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	0	USD
CY2013	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	15000000	USD
CY2012	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	17000000	USD
CY2011	thc	Proceeds From Sale Of Marketable Securities Long Term Investments And Other Assets ProceedsFromSaleOfMarketableSecuritiesLongTermInvestmentsAndOtherAssets	59000000	USD
CY2013	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	-8000000	USD
CY2012	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	9000000	USD
CY2011	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	2000000	USD
CY2013	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-3000000	USD
CY2012	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	-4000000	USD
CY2011	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1000000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-662000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-503000000	USD
CY2013	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1286000000	USD
CY2012	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1773000000	USD
CY2011	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	365000000	USD
CY2013	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	1691000000	USD
CY2011	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	445000000	USD
CY2013	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	5133000000	USD
CY2012	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	248000000	USD
CY2011	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	843000000	USD
CY2013	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	6507000000	USD
CY2012	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	1092000000	USD
CY2011	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	900000000	USD
CY2013	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2012	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	292000000	USD
CY2011	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2013	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	154000000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.40
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.08
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2012	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.30
CY2011	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.48
CY2011	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-15000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	25000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-9000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	-6000000	USD
CY2012	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	17000000	USD
CY2012	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	185000000	USD
CY2011	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	68000000	USD
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-11000000	USD
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-44000000	USD
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-10000000	USD
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	141000000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.21
CY2012	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.77
CY2011	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.58
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.11
CY2012	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.42
CY2011	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.09
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2012	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.35
CY2011	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.49
CY2013	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.21
CY2012	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.70
CY2011	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.56
CY2013	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.11
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	101648000	shares
CY2012	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104200000	shares
CY2011	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	117182000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101648000	shares
CY2012	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108926000	shares
CY2011	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121295000	shares
CY2013	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	-68000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	25000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax	15000000	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1000000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax	0	USD
CY2013	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	69000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-25000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	44000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-16000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-9000000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-60000000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	117000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	85000000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	30000000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-19000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	12000000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90000000	USD
CY2013	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	341000000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	125000000	USD
CY2012	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	10000000	USD
CY2013	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	46000000	USD
CY2012	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	59000000	USD
CY2011	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	35000000	USD
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	49000000	USD
CY2010Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1819000000	USD
CY2011Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1492000000	USD
CY2013Q4	thc	Indefinite Lived Intangible Assets Gross Excluding Goodwill IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill	1102000000	USD
CY2013	thc	Gain Loss Total Related To Litigation Settlement GainLossTotalRelatedToLitigationSettlement	-33000000	USD
CY2012	thc	Gain Loss Total Related To Litigation Settlement GainLossTotalRelatedToLitigationSettlement	-5000000	USD
CY2011	thc	Gain Loss Total Related To Litigation Settlement GainLossTotalRelatedToLitigationSettlement	-72000000	USD
CY2013	thc	Business Combination Acquisition Transaction Related Costs BusinessCombinationAcquisitionTransactionRelatedCosts	52000000	USD
CY2012	thc	Business Combination Acquisition Transaction Related Costs BusinessCombinationAcquisitionTransactionRelatedCosts	6000000	USD
CY2011	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	10000000	USD
CY2012	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	12000000	USD
CY2013	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	22000000	USD
CY2011	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	14000000	USD
CY2012	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	37000000	USD
CY2013	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	105000000	USD
CY2011	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	374000000	USD
CY2012	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	126000000	USD
CY2013	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	400000000	USD
CY2012	thc	Preferred Stock Repurchased During Period Value PreferredStockRepurchasedDuringPeriodValue	289000000	USD
CY2012	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2011	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	-18000000	USD
CY2012	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	92000000	USD
CY2011	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	81000000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	36000000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	32000000	USD
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	24000000	USD
CY2013	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	19000000	USD
CY2012	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	22000000	USD
CY2011	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	30000000	USD
CY2013	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-7000000	USD
CY2012	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-101000000	USD
CY2011	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-41000000	USD
CY2013	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	33000000	USD
CY2012	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	12000000	USD
CY2011	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	13000000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1060000000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	868000000	USD
CY2011	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	850000000	USD
CY2013	thc	Increase Decrease In Inventories And Other Assets Current IncreaseDecreaseInInventoriesAndOtherAssetsCurrent	130000000	USD
CY2013	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2012	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	5000000	USD
CY2011	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	63000000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	38000000	USD
CY2011	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-32000000	USD
CY2013	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	13000000	USD
CY2012	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3000000	USD
CY2011	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-5000000	USD
CY2013	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	114000000	USD
CY2012	thc	Payments For Restructuring And Litigation Costs PaymentsForRestructuringAndLitigationCosts	63000000	USD
CY2011	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	21000000	USD
CY2012	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	126000000	USD
CY2011	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	374000000	USD
CY2013	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	0	USD
CY2012	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	14000000	USD
CY2011	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	24000000	USD
CY2013	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	27000000	USD
CY2012	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	15000000	USD
CY2011	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	10000000	USD
CY2013	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	99000000	USD
CY2012	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	3000000	USD
CY2011	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	22000000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11000000	USD
CY2011	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000000	USD
CY2013	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	5000000	USD
CY2012	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	6000000	USD
CY2011	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	3000000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1324000000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	320000000	USD
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-286000000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-251000000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	251000000	USD
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-292000000	USD
CY2013	us-gaap	Interest Paid Net InterestPaidNet	-426000000	USD
CY2012	us-gaap	Interest Paid Net InterestPaidNet	-376000000	USD
CY2011	us-gaap	Interest Paid Net InterestPaidNet	-347000000	USD
CY2013	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	0	USD
CY2012	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	0	USD
CY2011	thc	Proceeds From Interest Rate Swap Agreement ProceedsFromInterestRateSwapAgreement	30000000	USD
CY2013	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-6000000	USD
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-13000000	USD
CY2011	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-10000000	USD
CY2013Q2	dei	Entity Public Float EntityPublicFloat	3900000000	USD
CY2013	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2013	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2013	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	405000000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	113000000	USD
CY2013	dei	Entity Registrant Name EntityRegistrantName	TENET HEALTHCARE CORP
CY2013	dei	Entity Central Index Key EntityCentralIndexKey	0000070318
CY2013	dei	Document Type DocumentType	10-K
CY2013	dei	Document Period End Date DocumentPeriodEndDate	2013-12-31
CY2011	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	84000000	USD
CY2013	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	96989632	shares
CY2013	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	364000000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2038000000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1345000000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	262000000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	153000000	USD
CY2013Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2012Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	581000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	354000000	USD
CY2013Q4	us-gaap	Other Assets Current OtherAssetsCurrent	716000000	USD
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	458000000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	3710000000	USD
CY2012	thc	Income Tax Expense Due To Increase In Liabilities For Uncertain Tax Positions IncomeTaxExpenseDueToIncreaseInLiabilitiesForUncertainTaxPositions	3000000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	2681000000	USD
CY2012Q4	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	162000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	90000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	342000000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7691000000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4293000000	USD
CY2013Q4	us-gaap	Goodwill Goodwill	3042000000	USD
CY2012Q4	us-gaap	Goodwill Goodwill	916000000	USD
CY2013Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1192000000	USD
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	650000000	USD
CY2013Q4	us-gaap	Assets Assets	16130000000	USD
CY2012Q4	us-gaap	Assets Assets	9044000000	USD
CY2013Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	149000000	USD
CY2012Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	94000000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1075000000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	722000000	USD
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	631000000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	415000000	USD
CY2013Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	156000000	USD
CY2012Q4	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	64000000	USD
CY2013	thc	Minimum Number Of Hospitals To Which Business Process Solution Is Provided By Subsidiaries MinimumNumberOfHospitalsToWhichBusinessProcessSolutionIsProvidedBySubsidiaries	700	item
CY2013	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></i></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The preparation of financial statements, in conformity with accounting principles generally accepted in the United States of America (“GAAP”), requires us to make estimates and assumptions that affect the amounts reported in our Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Although we believe all adjustments considered necessary for a fair presentation have been included, actual results may vary from those estimates. Financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public.</font></p> </div>
CY2013	us-gaap	Revenue Recognition Sales Of Services RevenueRecognitionSalesOfServices	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><i><font style="FONT-STYLE: italic; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net Operating Revenues Before Provision for Doubtful Accounts</font></i></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We recognize net operating revenues before provision for doubtful accounts in the period in which our services are performed. Net operating revenues before provision for doubtful accounts primarily consist of net patient service revenues that are recorded based on established billing rates (i.e., gross charges), less estimated discounts for contractual and other allowances, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our</font><i><font style="FONT-STYLE: italic; FONT-SIZE: 10pt;" size="2">Compact with Uninsured Patients</font></i> <font style="FONT-SIZE: 10pt;" size="2">(“Compact”) and other uninsured discount and charity programs</font><font style="FONT-SIZE: 10pt;" size="2">.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Gross charges are retail charges. They are not the same as actual pricing, and they generally do not reflect what a hospital is ultimately paid and, therefore, are not displayed in our consolidated statements of operations. Hospitals are typically paid amounts that are negotiated with insurance companies or are set by the government. Gross charges are used to calculate Medicare outlier payments and to determine certain elements of payment under managed care contracts (such as stop-loss payments). Because Medicare requires that a hospital’s gross charges be the same for all patients (regardless of payer category), gross charges are also what hospitals charge all other patients prior to the application of discounts and allowances.</font></p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenues under the traditional fee-for-service Medicare and Medicaid programs are based primarily on prospective payment systems. Retrospectively determined cost-based revenues under these programs, which were more prevalent in earlier periods, and certain other payments, such as Indirect Medical Education, Direct Graduate Medical Education, disproportionate share hospital and bad debt expense, which are based on our hospitals’ cost reports, are estimated using historical trends and current factors. Cost report settlements under these programs are subject to audit by Medicare and Medicaid auditors and administrative and judicial review, and it can take several years until final settlement of such matters is determined and completely resolved. Because the laws, regulations, instructions and rule interpretations governing Medicare and Medicaid reimbursement are complex and change frequently, the estimates recorded by us could change by material amounts.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We have a system and estimation process for recording Medicare net patient revenue and estimated cost report settlements. This results in us recording accruals to reflect the expected final settlements on our cost reports. For filed cost reports, we record the accrual based on those cost reports and subsequent activity, and record a valuation allowance against those cost reports based on historical settlement trends. The accrual for periods for which a cost report is yet to be filed is recorded based on estimates of what we expect to report on the filed cost reports, and a corresponding valuation allowance is recorded as previously described. Cost reports generally must be filed within five months after the end of the annual cost reporting period. After the cost report is filed, the accrual and corresponding valuation allowance may need to be adjusted. Adjustments for prior-year cost reports and related valuation allowances, principally related to Medicare and Medicaid, increased revenues in the years ended December 31, 2013, 2012 and 2011 by $38 million, $114 million ($81 million related to the industry-wide Medicare Budget Neutrality settlement), and $1 million, respectively. Estimated cost report settlements and valuation allowances are included in accounts receivable in the accompanying Consolidated Balance Sheets (see Note 3). We believe that we have made adequate provision for any adjustments that may result from final determination of amounts earned under all the above arrangements with Medicare and Medicaid.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Revenues under managed care plans are based primarily on payment terms involving predetermined rates per diagnosis, per-diem rates, discounted fee-for-service rates and/or other similar contractual arrangements. These revenues are also subject to review and possible audit by the payers, which can take several years before they are completely resolved. The payers are billed for patient services on an individual patient basis. An individual patient’s bill is subject to adjustment on a patient-by-patient basis in the ordinary course of business by the payers following their review and adjudication of each particular bill. We estimate the discounts for contractual allowances at the individual hospital level utilizing billing data on an individual patient basis. At the end of each month, on an individual hospital basis, we estimate our expected reimbursement for patients of managed care plans based on the applicable contract terms. Contractual allowance estimates are periodically reviewed for accuracy by taking into consideration known contract terms as well as payment history. Although we do not separately accumulate and disclose the aggregate amount of adjustments to the estimated reimbursement for every patient bill, we believe our estimation and review process enables us to identify instances on a timely basis where such estimates need to be revised. We do not believe there were any adjustments to estimates of patient bills that were material to our revenues. In addition, on a corporate-wide basis, we do not record any general provision for adjustments to estimated contractual allowances for managed care plans. Managed care accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for these payers and other factors that affect the estimation process.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We know of no material claims, disputes or unsettled matters with any payer that would affect our revenues for which we have not adequately provided for in the accompanying Consolidated Financial Statements.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Under our Compact or other uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual allowance, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual allowances recorded, are further reduced to their net realizable value through provision for doubtful accounts based on historical collection trends for self-pay accounts and other factors that affect the estimation process.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">We also provide charity care to patients who are financially unable to pay for the health care services they receive. Most patients who qualify for charity care are charged a per-diem amount for services received, subject to a cap. Except for the per-diem amounts, our policy is not to pursue collection of amounts determined to qualify as charity care; therefore, we do not report these amounts in net operating revenues or in provision for doubtful accounts. Patient advocates from Conifer’s Medical Eligibility Program screen patients in the hospital to determine whether those patients meet eligibility requirements for financial assistance programs. They also expedite the process of applying for these government programs.</font></p> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p> <p style="TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The table below shows the sources of net operating revenues before provision for doubtful accounts from continuing operations:</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <table style="text-align:left;WIDTH: 100%; BORDER-COLLAPSE: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 41%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="41%" colspan="8"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">Years Ended December 31,</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2013</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2012</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt; FONT-WEIGHT: bold;" size="1">2011</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="TEXT-ALIGN: center; MARGIN: 0in 0in 0pt;" align="center"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">General Hospitals:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: medium none; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medicare</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,357</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,195</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">$</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">2,068</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Medicaid</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">975</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">783</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">802</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Managed care</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">6,277</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,382</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">5,128</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Indemnity, self-pay and other</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,201</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,007</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">958</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Acute care hospitals — other revenue</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">78</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">69</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">105</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Other:</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"> </p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 20pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Other operations</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">1,186</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">468</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 1pt solid; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 12%; PADDING-RIGHT: 0in; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" valign="bottom" width="12%" colspan="2"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">310</font></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; PADDING-TOP: 0in;" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr> <tr style="padding:0;"> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 55.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="55%"> <p style="TEXT-INDENT: -10pt; MARGIN: 0in 0in 0pt 10pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Net operating revenues before provision for doubtful accounts</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">12,074</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">9,904</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 2.5%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="2%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1.3%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: medium none; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">$</font></b></p></td> <td style="BORDER-BOTTOM: windowtext 2.25pt double; BORDER-LEFT: medium none; PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 10.7%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; BORDER-TOP: windowtext 1pt solid; BORDER-RIGHT: medium none; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="10%"> <p style="TEXT-ALIGN: right; MARGIN: 0in 0in 0pt;" align="right"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">9,371</font></b></p></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 1%; PADDING-RIGHT: 0in; BACKGROUND: #cceeff; PADDING-TOP: 0in;" bgcolor="#CCEEFF" valign="bottom" width="1%"> <p style="MARGIN: 0in 0in 0pt;"> </p></td></tr></table> </div>
CY2012	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.0118	pure
CY2013	thc	Cost Report Filing Period After End Of Annual Cost Reporting Period CostReportFilingPeriodAfterEndOfAnnualCostReportingPeriod	P5M
CY2012	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	114000000	USD
CY2011	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	1000000	USD
CY2013	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowances	38000000	USD
CY2012	thc	Increase In Revenue Due To Adjustments For Prior Year Cost Reports And Related Valuation Allowances Related To Industry Wide Medicare Rural Floor Budget Neutrality Adjustment Settlement IncreaseInRevenueDueToAdjustmentsForPriorYearCostReportsAndRelatedValuationAllowancesRelatedToIndustryWideMedicareRuralFloorBudgetNeutralityAdjustmentSettlement	81000000	USD
CY2013Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	245000000	USD
CY2013	thc	Period For Use Of Ehr Technology To Become Eligible For Annual Medicare Incentive Payments PeriodForUseOfEHRTechnologyToBecomeEligibleForAnnualMedicareIncentivePayments	P4Y
CY2013	thc	Percentage Of Medicaid Incentive Payments Federally Funded PercentageOfMedicaidIncentivePaymentsFederallyFunded	1.00	pure
CY2012	thc	Incentive Payments For Technology Certification IncentivePaymentsForTechnologyCertification	40000000	USD
CY2013	thc	Incentive Payments For Technology Certification IncentivePaymentsForTechnologyCertification	96000000	USD
CY2011	thc	Incentive Payments For Technology Certification IncentivePaymentsForTechnologyCertification	55000000	USD
CY2012Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	232000000	USD
CY2012Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	65000000	USD
CY2012	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	88000000	USD
CY2013Q4	thc	Cash And Cash Equivalents Related To Captive Insurance Subsidiaries CashAndCashEquivalentsRelatedToCaptiveInsuranceSubsidiaries	62000000	USD
CY2013Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	796000	shares
CY2013	thc	Property Plant And Equipment Additions Minimum Useful Life PropertyPlantAndEquipmentAdditionsMinimumUsefulLife	P1Y
CY2012	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	6000000	USD
CY2011	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	8000000	USD
CY2013	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	14000000	USD
CY2011	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.967	pure
CY2012	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.953	pure
CY2013	thc	Percentage Of Net Operating Revenues Generated By General Hospitals PercentageOfNetOperatingRevenuesGeneratedByGeneralHospitals	0.902	pure
CY2013Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	166000	shares
CY2013Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1045000	shares
CY2013	us-gaap	Malpractice Loss Contingency Discount Rate MalpracticeLossContingencyDiscountRate	0.0245	pure
CY2012Q4	us-gaap	Stock Repurchase Program Authorized Amount StockRepurchaseProgramAuthorizedAmount	500000000	USD
CY2013Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2642000	shares
CY2012Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	3406000	shares
CY2013Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	531000	shares
CY2013Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	914000	shares
CY2013Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1010000	shares
CY2013Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2455000	shares
CY2013Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	933000	shares
CY2013Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1065000	shares
CY2013Q3	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1431000	shares
CY2013Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1998000	shares
CY2013Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	40.75
CY2012Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	29.36
CY2013Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	37.13
CY2013Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	39.30
CY2013Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	43.95
CY2013Q1	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	40.74
CY2013Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	46.78
CY2013Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	45.71
CY2013Q2	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	46.21
CY2013Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	46.08
CY2013Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	40.43
CY2013Q3	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	40.35
	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	38.79
	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	12891000	shares
CY2013Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	100000000	USD
CY2012Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	400000000	USD
CY2013Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	380000000	USD
CY2013	thc	Allowance For Doubtful Accounts As Percent Of Accounts Receivable AllowanceForDoubtfulAccountsAsPercentOfAccountsReceivable	0.232	pure
CY2012	thc	Allowance For Doubtful Accounts As Percent Of Accounts Receivable AllowanceForDoubtfulAccountsAsPercentOfAccountsReceivable	0.237	pure
CY2013	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	103000000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	37000000	USD
CY2013Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	344000000	USD
CY2013Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	300000000	USD
CY2013Q1	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	300000000	USD
CY2013Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	256000000	USD
CY2013Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	208000000	USD
CY2013Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	208000000	USD
CY2013Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	200000000	USD
CY2013Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	158000000	USD
CY2013Q3	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	100000000	USD
	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	0	USD
CY2012Q2	thc	Preferred Stock Seven Percent Mandatory Convertible Shares Retired PreferredStockSevenPercentMandatoryConvertibleSharesRetired	298700	shares
CY2013Q4	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2012Q2	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	289000000	USD
CY2012Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	46300	shares
CY2012Q2	us-gaap	Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax	2000000	USD
CY2013	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	7000000	USD
CY2012	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	154000000	USD
CY2011	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	216000000	USD
CY2011	thc	Litigation Settlements Net Of Insurance Recoveries LitigationSettlementsNetOfInsuranceRecoveries	14000000	USD
CY2011	us-gaap	Insurance Recoveries InsuranceRecoveries	10000000	USD
CY2010Q4	us-gaap	Litigation Reserve LitigationReserve	5000000	USD
CY2011	us-gaap	Loss Contingency Accrual Carrying Value Period Increase Decrease LossContingencyAccrualCarryingValuePeriodIncreaseDecrease	17000000	USD
CY2011	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	20000000	USD
CY2013	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2012	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	19000000	USD
CY2013	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	59000000	USD
CY2012	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3000000	USD
CY2013	us-gaap	Severance Costs1 SeveranceCosts1	14000000	USD
CY2012	us-gaap	Severance Costs1 SeveranceCosts1	8000000	USD
CY2012	us-gaap	Other Restructuring Costs OtherRestructuringCosts	6000000	USD
CY2013	us-gaap	Business Exit Costs1 BusinessExitCosts1	2000000	USD
CY2011Q4	us-gaap	Assets Held For Sale Long Lived AssetsHeldForSaleLongLived	20000000	USD
CY2013	us-gaap	Restructuring Charges RestructuringCharges	16000000	USD
CY2013	us-gaap	Defined Benefit Plans Estimated Future Employer Contributions In Next Fiscal Year DefinedBenefitPlansEstimatedFutureEmployerContributionsInNextFiscalYear	28000000	USD
CY2011	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-6000000	USD
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	117000000	USD
CY2011	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	62000000	USD
CY2012	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2012Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10000000	USD
CY2011Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	66000000	USD
CY2010Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	30000000	USD
CY2013Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	46000000	USD
CY2012	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	61000000	USD
CY2011	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	36000000	USD
CY2013	us-gaap	Loss Contingency Accrual Carrying Value Payments LossContingencyAccrualCarryingValuePayments	11000000	USD
CY2013	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2000000	USD
CY2013	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	4000000	USD
CY2013	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6000000	USD
CY2013	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-56000000	USD
CY2013	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-15000000	USD
CY2013	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-71000000	USD
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-3000000	USD
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2012	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000000	USD
CY2011	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-6000000	USD
CY2012	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8000000	USD
CY2011	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	5000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	107000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1610000000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	678000000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	53000000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	163000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Financing Arrangements DeferredTaxLiabilitiesFinancingArrangements	53000000	USD
CY2012	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	117000000	USD
CY2011	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	67000000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-55000000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1000000	USD
CY2013	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	10000000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2000000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-7000000	USD
CY2013	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	-3000000	USD
CY2013	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1000000	USD
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	117000000	USD
CY2011	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	57000000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	13000000	USD
CY2011	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	10000000	USD
CY2012	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	4000000	USD
CY2011	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	4000000	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-5000000	USD
CY2011	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2000000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-1000000	USD
CY2011	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	-12000000	USD
CY2012	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	-3000000	USD
CY2011	thc	Income Tax Reconciliation Prior Year Income Taxes And Change In Deferred Taxes IncomeTaxReconciliationPriorYearIncomeTaxesAndChangeInDeferredTaxes	-7000000	USD
CY2012	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	2000000	USD
CY2011	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	5000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	5000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges	20000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	209000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance	288000000	USD
CY2013Q4	thc	Deferred Tax Assets Other Long Term Liabilities DeferredTaxAssetsOtherLongTermLiabilities	76000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	299000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	60000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	708000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	28000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	29000000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1717000000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	939000000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	671000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	173000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Self Insurance DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance	182000000	USD
CY2012Q4	thc	Deferred Tax Assets Other Long Term Liabilities DeferredTaxAssetsOtherLongTermLiabilities	55000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits	214000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	11000000	USD
CY2012Q4	thc	Deferred Tax Assets Investments And Other Assets DeferredTaxAssetsInvestmentsAndOtherAssets	6000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	588000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	32000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	36000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	122000000	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	550000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	1302000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	56000000	USD
CY2012Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	1246000000	USD
CY2013	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	0.00
CY2012	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	185000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2011	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	68000000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-123000000	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2876000	shares
CY2012Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	375000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	12000000	USD
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3421000	shares
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	3000000	USD
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	755000	shares
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	35000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	35000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities	0	USD
CY2011	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	4000000	USD
CY2013	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2012Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	696000000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations	7000000	USD
CY2012	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	4726000	shares
CY2011	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	4113000	shares
CY2013Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	34000000	USD
CY2011Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	35000000	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	32000000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	5000000	USD
CY2013	us-gaap	Incremental Common Shares Attributable To Conversion Of Preferred Stock IncrementalCommonSharesAttributableToConversionOfPreferredStock	0	shares
CY2012	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.07
CY2011	thc	Effect Of Dilutive Stock Options Restricted Stock Units And Mandatory Convertible Preferred Stock Per Share Amount EffectOfDilutiveStockOptionsRestrictedStockUnitsAndMandatoryConvertiblePreferredStockPerShareAmount	-0.02
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	32000000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	43000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	15000000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	15000000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2011	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000000	USD
CY2012	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	2000000	USD
CY2013	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	3000000	USD
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2013Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	1000000	USD
CY2013	thc	Operating Loss Carryforward Limitation On Use Percent Of Shareholders OperatingLossCarryforwardLimitationOnUsePercentOfShareholders	0.05	pure
CY2013	thc	Operating Loss Carryforward Limitation On Use Measurement Period OperatingLossCarryforwardLimitationOnUseMeasurementPeriod	P3Y
CY2012	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2011	us-gaap	Amount Of Dilutive Securities Stock Options And Restrictive Stock Units AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits	0	USD
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4000000	USD
CY2013Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1000000	USD
CY2012Q4	us-gaap	Alternative Investments Fair Value Disclosure AlternativeInvestmentsFairValueDisclosure	2000000	USD
CY2013Q4	us-gaap	Alternative Investments Fair Value Disclosure AlternativeInvestmentsFairValueDisclosure	2000000	USD
CY2013	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	25000000	USD
CY2012Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	14000000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	62000000	USD
CY2012Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	20000000	USD
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	65000000	USD
CY2013Q4	thc	Preferred Stock And Other Securities Held By Captive Insurance Subsidiaries PreferredStockAndOtherSecuritiesHeldByCaptiveInsuranceSubsidiaries	1000000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	398000000	USD
CY2012Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.082	pure
CY2013Q4	thc	Estimated Fair Value Of Debt Instrument As Percentage Of Carrying Value EstimatedFairValueOfDebtInstrumentAsPercentageOfCarryingValue	1.035	pure
CY2012	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	6000000	USD
CY2013	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2013	thc	Number Of Hospitals Owned By Subsidiaries NumberOfHospitalsOwnedBySubsidiaries	77	item
CY2013	thc	Number Of Licensed Beds In Hospitals Operated By The Subsidiaries NumberOfLicensedBedsInHospitalsOperatedByTheSubsidiaries	20293	item
CY2013	thc	Number Of Provider Based Out Patient Centers Operated By Subsidiaries NumberOfProviderBasedOutPatientCentersOperatedBySubsidiaries	183	item
CY2011Q4	us-gaap	Assets Assets	8462000000	USD
CY2013	thc	Capital Expenditure CapitalExpenditure	691000000	USD
CY2012	thc	Capital Expenditure CapitalExpenditure	508000000	USD
CY2011	thc	Capital Expenditure CapitalExpenditure	475000000	USD
CY2013	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	11102000000	USD
CY2012	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	9119000000	USD
CY2011	us-gaap	Health Care Organization Patient Service Revenue Less Provision For Bad Debts HealthCareOrganizationPatientServiceRevenueLessProvisionForBadDebts	8654000000	USD
CY2013	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1342000000	USD
CY2012	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1203000000	USD
CY2011	thc	Adjusted Earnings Before Interest Tax Depreciation And Amortization AdjustedEarningsBeforeInterestTaxDepreciationAndAmortization	1126000000	USD
CY2013	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	-158000000	USD
CY2012	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	334000000	USD
CY2011	thc	Adjusted Earnings Before Income Tax AdjustedEarningsBeforeIncomeTax	164000000	USD
CY2012	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	3000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax	-25000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansTax	9000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositions	21000000	USD
CY2013	thc	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense To Continuing Operations UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpenseToContinuingOperations	1000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Continuing Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsContinuingOperations	2000000	USD
CY2011	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Discontinued Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsDiscontinuedOperations	19000000	USD
CY2012Q4	thc	Stockholders Equity Reverse Stock Split Conversion Ratio StockholdersEquityReverseStockSplitConversionRatio	0.25	shares
CY2013Q4	thc	Common Stock Shares Authorized Before Reverse Stock Split CommonStockSharesAuthorizedBeforeReverseStockSplit	1050000000	shares
CY2013	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	5000000	USD
CY2013	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	103000000	USD
CY2012	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	19000000	USD
CY2012	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2012	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2013	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	-44000000	USD
CY2012	us-gaap	Defined Benefit Plan Actuarial Gain Loss DefinedBenefitPlanActuarialGainLoss	30000000	USD
CY2013	us-gaap	Defined Benefit Plan Benefits Paid DefinedBenefitPlanBenefitsPaid	-11000000	USD
CY2013Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	41.62
CY2013Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	41.84
CY2012	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	25000000	USD
CY2012	us-gaap	Defined Benefit Plan Benefits Paid DefinedBenefitPlanBenefitsPaid	0	USD
CY2013Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	886000000	USD
CY2013Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	66000000	USD
CY2012	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	2000000	USD
CY2011	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	6000000	USD
CY2011	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	1000000	USD
CY2011Q4	us-gaap	Cost Method Investments CostMethodInvestments	1000000	USD
CY2011	us-gaap	Severance Costs1 SeveranceCosts1	7000000	USD
CY2011	us-gaap	Business Exit Costs1 BusinessExitCosts1	3000000	USD
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1000000	USD
CY2011	us-gaap	Other Restructuring Costs OtherRestructuringCosts	1000000	USD
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3308111	shares
CY2013	thc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentage	1.000	pure
CY2013	thc	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Percentage Of Total ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPercentageOfTotal	1.000	pure
CY2013Q4	thc	Common Stock Fair Value Per Share CommonStockFairValuePerShare	42.12
CY2012	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	32000000	USD
CY2011	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	32000000	USD
CY2013	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	35000000	USD
CY2013	thc	Defined Benefit Pension Plan Active Number DefinedBenefitPensionPlanActiveNumber	1	item
CY2013	thc	Defined Benefit Pension Plan Frozen Number DefinedBenefitPensionPlanFrozenNumber	2	item
CY2011Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	285000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	312000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Benefit Obligation DefinedBenefitPlanBenefitObligation	1303000000	USD
CY2013	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	15000000	USD
CY2012Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent	292000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	22000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Net Unamortized Gain Loss Arising During Period Before Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax	-68000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	0	USD
CY2013Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	417000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Funded Status Of Plan DefinedBenefitPlanFundedStatusOfPlan	312000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-395000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax	90000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Amounts Recognized In Balance Sheet DefinedBenefitPlanAmountsRecognizedInBalanceSheet	-222000000	USD
CY2012	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	-30000000	USD
CY2011	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	-19000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	308000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Accumulated Benefit Obligation DefinedBenefitPlanAccumulatedBenefitObligation	1297000000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Before Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax	63000000	USD
CY2012Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-90000000	USD
CY2011	us-gaap	Defined Benefit Plan Service Cost DefinedBenefitPlanServiceCost	2000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-65000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Accumulated Other Comprehensive Income Net Gains Losses Before Tax DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax	-21000000	USD
CY2011	us-gaap	Defined Benefit Plan Interest Cost DefinedBenefitPlanInterestCost	14000000	USD
CY2013	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	-15000000	USD
CY2012	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2013Q4	thc	Defined Benefit Plan Expected Future Benefit Payments DefinedBenefitPlanExpectedFutureBenefitPayments	841000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Next Twelve Months DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths	88000000	USD
CY2013Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	19000000	USD
CY2012Q4	us-gaap	Pension And Other Postretirement Defined Benefit Plans Current Liabilities PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities	20000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Two DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo	74000000	USD
CY2011	us-gaap	Defined Benefit Plan Amortization Of Prior Service Cost Credit DefinedBenefitPlanAmortizationOfPriorServiceCostCredit	0	USD
CY2013	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-7000000	USD
CY2012	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-5000000	USD
CY2011	us-gaap	Defined Benefit Plan Amortization Of Gains Losses DefinedBenefitPlanAmortizationOfGainsLosses	-3000000	USD
CY2013	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	19000000	USD
CY2012	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	21000000	USD
CY2011	us-gaap	Defined Benefit Plan Net Periodic Benefit Cost DefinedBenefitPlanNetPeriodicBenefitCost	19000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Three DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree	76000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Four DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour	80000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Year Five DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive	82000000	USD
CY2013Q4	us-gaap	Defined Benefit Plan Expected Future Benefit Payments Five Fiscal Years Thereafter DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter	441000000	USD
CY2012Q4	thc	Fractional Stock Issued During Period Shares Reverse Stock Splits FractionalStockIssuedDuringPeriodSharesReverseStockSplits	0	shares
CY2012Q2	thc	Percentage Of Mandatory Convertible Shares PercentageOfMandatoryConvertibleShares	0.07	pure
CY2013Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1594000	shares
CY2013Q4	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	2390000	shares
CY2013Q4	us-gaap	Treasury Stock Acquired Average Cost Per Share TreasuryStockAcquiredAverageCostPerShare	42.28
CY2013Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	0	USD
CY2013Q4	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount	0	USD
CY2011	thc	Restructuring Settlement Impairment Provisions And Acquisition Cost RestructuringSettlementImpairmentProvisionsAndAcquisitionCost	20000000	USD
CY2013	thc	Number Of Health Plans Operated By Subsidiaries NumberOfHealthPlansOperatedBySubsidiaries	6	item
CY2013	thc	Income Tax Reconciliation Nondeductible Expense Transaction Costs IncomeTaxReconciliationNondeductibleExpenseTransactionCosts	6000000	USD
CY2012	thc	Income Tax Reconciliation Nondeductible Expense Transaction Costs IncomeTaxReconciliationNondeductibleExpenseTransactionCosts	0	USD
CY2011	thc	Income Tax Reconciliation Nondeductible Expense Transaction Costs IncomeTaxReconciliationNondeductibleExpenseTransactionCosts	0	USD
CY2011	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5000000	USD
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5000000	USD
CY2013	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	51000000	USD
CY2013	thc	Valuation Allowance Deferred Tax Asset Change In Amount Attributable To Business Combination ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToBusinessCombination	34000000	USD
CY2011Q4	us-gaap	Defined Benefit Plan Fair Value Of Plan Assets DefinedBenefitPlanFairValueOfPlanAssets	0	USD
CY2013	thc	Valuation Allowance Deferred Tax Asset Change In Amount Attributable To State Net Operating Loss Carryforwards ValuationAllowanceDeferredTaxAssetChangeInAmountAttributableToStateNetOperatingLossCarryforwards	17000000	USD
CY2013	thc	Income Tax Benefit Due To Reduction Of Liabilities For Uncertain Tax Positions Continuing Operations IncomeTaxBenefitDueToReductionOfLiabilitiesForUncertainTaxPositionsContinuingOperations	1000000	USD
CY2013	thc	Number Of Accountable Care Organizations Operated By Subsidiaries NumberOfAccountableCareOrganizationsOperatedBySubsidiaries	6	item
CY2013	us-gaap	Defined Benefit Plan Business Combinations And Acquisitions Benefit Obligation DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation	1037000000	USD
CY2012	us-gaap	Defined Benefit Plan Business Combinations And Acquisitions Benefit Obligation DefinedBenefitPlanBusinessCombinationsAndAcquisitionsBenefitObligation	0	USD
CY2013	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	2000000	USD
CY2012	us-gaap	Defined Benefit Plan Plan Amendments DefinedBenefitPlanPlanAmendments	0	USD
CY2013	thc	Defined Benefit Plan Benefits Paid Or Employer Contribution DefinedBenefitPlanBenefitsPaidOrEmployerContribution	31000000	USD
CY2012	thc	Defined Benefit Plan Benefits Paid Or Employer Contribution DefinedBenefitPlanBenefitsPaidOrEmployerContribution	19000000	USD
CY2013	us-gaap	Defined Benefit Plan Business Combinations And Acquisitions Plan Assets DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets	863000000	USD
CY2012	us-gaap	Defined Benefit Plan Business Combinations And Acquisitions Plan Assets DefinedBenefitPlanBusinessCombinationsAndAcquisitionsPlanAssets	0	USD
CY2013	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	34000000	USD
CY2012	us-gaap	Defined Benefit Plan Actual Return On Plan Assets DefinedBenefitPlanActualReturnOnPlanAssets	0	USD
CY2013Q4	thc	Deferred Tax Liabilities Investments And Other Assets DeferredTaxLiabilitiesInvestmentsAndOtherAssets	45000000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	500000000	USD
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	98000000	USD
CY2013	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	193000000	USD
CY2012Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	93000000	USD
CY2013Q4	thc	Capital Expenditures Incurred But Not Yet Paid Current CapitalExpendituresIncurredButNotYetPaidCurrent	138000000	USD
CY2013	thc	Loss Contingency Reserves Assumed In Acquisition LossContingencyReservesAssumedInAcquisition	14000000	USD
CY2012	thc	Loss Contingency Reserves Assumed In Acquisition LossContingencyReservesAssumedInAcquisition	0	USD
CY2011	thc	Loss Contingency Reserves Assumed In Acquisition LossContingencyReservesAssumedInAcquisition	0	USD
CY2013	thc	Profit Loss Attributable To Nonredeemable Noncontrolling Interest ProfitLossAttributableToNonredeemableNoncontrollingInterest	-113000000	USD
CY2012	thc	Profit Loss Attributable To Nonredeemable Noncontrolling Interest ProfitLossAttributableToNonredeemableNoncontrollingInterest	130000000	USD
CY2011	thc	Profit Loss Attributable To Nonredeemable Noncontrolling Interest ProfitLossAttributableToNonredeemableNoncontrollingInterest	94000000	USD

Files In Submission

Name	View Source	Status
0001104659-14-012768-index-headers.html	Edgar Link	pending
0001104659-14-012768-index.html	Edgar Link	pending
0001104659-14-012768.txt	Edgar Link	pending
0001104659-14-012768-xbrl.zip	Edgar Link	pending
a13-26042_110k.htm	Edgar Link	pending
a13-26042_1ex10dc.htm	Edgar Link	pending
a13-26042_1ex10dj.htm	Edgar Link	pending
a13-26042_1ex21.htm	Edgar Link	pending
a13-26042_1ex23.htm	Edgar Link	pending
a13-26042_1ex31da.htm	Edgar Link	pending
a13-26042_1ex31db.htm	Edgar Link	pending
a13-26042_1ex32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
g260421boi001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
thc-20131231.xml	Edgar Link	completed
thc-20131231.xsd	Edgar Link	pending
thc-20131231_cal.xml	Edgar Link	unprocessable
thc-20131231_def.xml	Edgar Link	unprocessable
thc-20131231_lab.xml	Edgar Link	unprocessable
thc-20131231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$THC
TENET HEALTHCARE CORP Stock $thc

2014 Q1 Form 10-K Financial Statement

#000110465914012768 Filed on February 24, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC TENET HEALTHCARE CORP Stock $thc

2014 Q1 Form 10-K Financial Statement

#000110465914012768 Filed on February 24, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$THC
TENET HEALTHCARE CORP Stock $thc